The Fenlix Motor — A Validated Pipeline for Kinase Inhibitor Selectivity Prediction Case II: Exploiting CYS604 Evolutionary Divergence for Selective TcCLK1 Inhibition in Chagas Disease

Read full text Summarise with VIRAT
Authors: Andrés Sebastián Pirolo
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Abstract Chagas disease, caused by Trypanosoma cruzi, affects millions across Latin America but remains a neglected tropical disease due to chronic market failure in pharmaceutical development. The parasite relies on the TcCLK1 kinase for essential pre-mRNA splicing, making it a validated drug target. However, achieving selectivity against structurally homologous human kinases (hCLK1/2/3) is critical to avoid severe toxicity. Using the Fenlix Motor—a validated Fibonacci-Axial SO(3) docking pipeline—we identified a universal geometric principle for kinase selectivity: the disruption of axial symmetry through meta-substituted hydrogen bond donors targeting evolutionarily divergent hinge residues. Screening structural analogues of the non-selective ligand NMS-P715 (SVE), we discovered that the hinge of TcCLK1 contains a unique Cysteine (CYS604), whereas human CLKs present Leucine, Tyrosine, or Aspartate at the equivalent position. Analogue E02_3NH2 leverages a meta-amino group to form a specific hydrogen bond with the CYS604 thiol, an interaction geometrically and chemically inaccessible to human off-targets, improving selectivity by 1.24×. A second lead, A04_CF3, achieves 1.18× improved selectivity while substituting the amino group for a trifluoromethyl bioisostere, offering superior predicted metabolic stability for oral administration. This meta-substituent mechanism perfectly mirrors our previous findings in DYRK1A (targeting GLU291), establishing it as a universal structural rule for kinome selectivity. Statement on Intellectual Property and Global Health: The chemical structures, SMILES coordinates, and binding rationales for E02_3NH2 and A04_CF3 are disclosed herein to establish formal Prior Art, intentionally preventing restrictive "Composition of Matter" patenting by private entities. This paper is explicitly tailored for global health organizations, including the DNDi (Drugs for Neglected Diseases initiative), the World Health Organization (WHO), the Bill & Melinda Gates Foundation, and public university consortiums. These organizations require exactly what is provided here: highly potent, rationally designed molecules that are free of patents, enabling unrestricted progression to in vitro synthesis, clinical development, and low-cost distribution in Latin America and Africa. The computational foundation is laid; the next step belongs to open-science chemistry.

Fields of Study & Subjects

Computational Drug Discovery Methods Trypanosoma species research and implications Synthesis and Characterization of Heterocyclic Compounds

Publication details

Journal / source
Zenodo (CERN European Organization for Nuclear Research)
Publication date
26 March 2026
Language
EN
Document type
Preprint